Total Revenue

+2.3% (from $13.617M in Q1 2024 to $13.919M in Q1 2025)

Modest revenue growth driven by underlying stability in both the Treatment and Services segments, maintaining similar contribution levels to prior periods. " "

Gross Profit

Improved by ~$1.277M (from -$620K in Q1 2024 to +$657K in Q1 2025)

Reversal of last year's margin weakness due to improved cost management and operational performance across segments, overcoming the negative margin experienced in the previous year. " "

Operating Loss

Narrowed by ~16% (from -$4,460K in Q1 2024 to -$3,736K in Q1 2025)

Improved operating performance stemming from tighter cost control initiatives and better project execution compared to the prior period, leading to a smaller operating loss. " "

R&D Expenses

Increased by nearly 29% (from $296K in Q1 2024 to $383K in Q1 2025)

A more aggressive investment in innovation reflects a strategic shift; the company is allocating additional funds to R&D relative to the previous period to fuel future growth. " "

Operating Cash Flow

Losses reduced by about 54% (from -$4,591K in Q1 2024 to -$2,104K in Q1 2025)

Significant improvement in cash flow efficiency was achieved through better operational management and expense controls, markedly reducing the negative cash flow compared to the prior period. " "

Cash

Declined ~11% (from $28,975K in Q4 2024 to $25,745K in Q1 2025)

An 11% drop in cash suggests increased cash deployment for operations or investments compared to the previous period, even though overall current assets remain healthy. " "